METXF
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company's lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, whic… Read more
METXF (METXF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of November 2025: -0.242x
Based on the latest financial reports, METXF (METXF) has a cash flow conversion efficiency ratio of -0.242x as of November 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-322.79K) by net assets ($1.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
METXF - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how METXF's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
METXF Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of METXF ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Windsor Machines Limited
NSE:WINDMACHIN
|
-0.057x |
|
Jin Air Co Ltd
KO:272450
|
0.154x |
|
Nitratos de Chile SA
SN:NITRATOS
|
0.085x |
|
BABYTREE GROUP
F:BTR
|
N/A |
|
Tecogen Inc.
NYSE:TGEN
|
-0.141x |
|
Asian Sea Corporation Public Company Limited
BK:ASIAN
|
0.060x |
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
-83.670x |
|
YASHO INDUSTRIES ORD (BSE)
NSE:YASHO
|
0.011x |
Annual Cash Flow Conversion Efficiency for METXF (2022–2025)
The table below shows the annual cash flow conversion efficiency of METXF from 2022 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-08-31 | $1.50 Million | $-862.35K | -0.574x | -28.68% |
| 2024-08-31 | $1.48 Million | $-657.92K | -0.446x | +23.04% |
| 2023-08-31 | $523.39K | $-303.19K | -0.579x | -54.78% |
| 2022-08-31 | $362.54K | $-135.69K | -0.374x | -- |